Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Petra Keikavoussi"'
Autor:
Rod Dunbar, Beatrice Schuler-Thurner, Jürgen Knop, Ina Haendle, Claudia Röder, Eckhart Kämpgen, Armin Bender, Helmut Jonuleit, Gerhard Schuler, Christian Maczek, Vincenzo Cerundolo, Eva-B. Bröcker, P. von den Driesch, Petra Keikavoussi, Waltraud Leisgang, Alexander Enk, Detlef Dieckmann
Publikováno v:
Scopus-Elsevier
Dendritic cell (DC) vaccination, albeit still in an early stage, is a promising strategy to induce immunity to cancer. We explored whether DC can expand Ag-specific CD8+ T cells even in far-advanced stage IV melanoma patients. We found that three to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74c6e2745b2bce21477b52d911544384
https://ora.ox.ac.uk/objects/uuid:b3385d39-f639-4e34-b662-f2c05b5b9375
https://ora.ox.ac.uk/objects/uuid:b3385d39-f639-4e34-b662-f2c05b5b9375
Publikováno v:
Acta Dermato Venereologica. 94:585-587
Autor:
Werner Rittgen, A Zimpfer, Andreas Hochhaus, Ralf Hildenbrand, Peter Paschka, Selma Ugurel, Dirk Schadendorf, Antje Sucker, Jürgen C. Becker, P La Rosée, Petra Keikavoussi
Publikováno v:
British Journal of Cancer
This two-centre phase-II trial aimed at investigating the efficacy of imatinib in metastasised melanoma patients in correlation to the tumour expression profile of the imatinib targets c-kit and platelet-derived growth factor receptor (PDGF-R). The p
Autor:
Eckhart Kämpgen, Eva-B. Bröcker, Lars Østergaard Pedersen, Andreas O. Eggert, Petra Keikavoussi, Mads Hald Andersen, Per thor Straten, Jürgen C. Becker, Markus Böck, Jörg Christian Rath, Kerstin Otto
Publikováno v:
Vaccine. 23:884-889
Prognosis of disseminated melanoma remains gloomy as neither chemotherapeutic nor unspecific immune modulatory approaches were able to improve the overall survival of these patients. Hence, specific immunotherapy has received increasing attention. Di
Autor:
Mads Hald Andersen, David Schrama, Per thor Straten, Jürgen C. Becker, Eckhart Kämpgen, Petra Keikavoussi, Eva-Bettina Bröcker, Lars Østergaard Pedersen
Publikováno v:
Journal of Investigative Dermatology. 119(6):1443-1448
Cellular immune responses are initiated by direct interaction of naive T cells with professional antigen-presenting cells, i.e., dendritic cells. In general, this interaction takes place in secondary lymphoid organs to which both naive T cells and ma
Autor:
Annette Kolb-Mäurer, C. Scheicher, Eckhart Kämpgen, Petra Keikavoussi, Hans-Werner Fries, Edgar Serfling, Eva-B. Bröcker, Manfred Neumann
Publikováno v:
Blood. 95:277-285
A key feature of maturation of dendritic cells is the down-regulation of antigen-processing and up-regulation of immunostimulatory capacities. To study the differential expression of transcription factors in this process, we investigated the nuclear
Autor:
Christian Maczek, Beatrice Thurner, Doris Schreiner, Eckhart Kämpgen, Peter von den Driesch, Detlef Dieckmann, Alexander Enk, Eva B. Bröcker, Helmut Jonuleit, Ralph M. Steinman, Gerold Schuler, Petra Keikavoussi, Ina Haendle, Armin Bender, Claudia Röder
Publikováno v:
The Journal of Experimental Medicine
Dendritic cells (DCs) are considered to be promising adjuvants for inducing immunity to cancer. We used mature, monocyte-derived DCs to elicit resistance to malignant melanoma. The DCs were pulsed with Mage-3A1 tumor peptide and a recall antigen, tet
Autor:
Jürgen C. Becker, Anke Hartmann, Petra Keikavoussi, Henning Hamm, Christina Bedenk, Eva-Bettina Bröcker
Publikováno v:
Journal der Deutschen Dermatologischen Gesellschaft. 6
Autor:
Petra Keikavoussi, Eva-Bettina Bröcker, Jürgen C. Becker, Anke Hartmann, Henning Hamm, Christina Bedenk
Publikováno v:
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 6(12)
Summary Background: It is unclear if differences between melanoma-associated hypopigmentation (MAH) and classical vitiligo exist. Patients and Methods: Hypopigmented areas and associated lesions (halo nevi, hypopigmented scars) in 15 melanoma patient
Autor:
Jürgen C. Becker, A. Tüttenberg, G. Burg, Antje Sucker, Werner Rittgen, Jivko Kamarashev, Dirk Schadendorf, Thomas G. Berger, Eckhart Kämpgen, Stephan Grabbe, Eva-B. Bröcker, C. Zimpfer-Rechner, Gerhard Schuler, Petra Keikavoussi, Lutz Edler, Helmut Jonuleit, Beatrice Schuler-Thurner, Alexander Enk, Frank O. Nestle, Selma Ugurel
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 17(4)
Background: This randomized phase III trial was designed to demonstrate the superiority of autologous peptide-loaded dendritic cell (DC) vaccination over standard dacarbazine (DTIC) chemotherapy in stage IV melanoma patients. Patients and methods: DT